rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KRYS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Abeona Therapeutics: My 'Buy The Dip' Call Backfired On Q3 Earnings: I'm Downgrading To Hold

      Abeona Therapeutics is rated a Hold, as Zevaskyn uptake and manufacturing remain uncertain, and its $135 million cash position could run out before 2028.

      5h agoSeeking AlphaKRYS
      Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates
      Nov 12Yahoo FinanceKRYSARMP
      Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan
      Nov 3Yahoo FinanceKRYS
      Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock

      Krystal Biotech reported Q3 2026 net income of US$63.07 million with diluted EPS of US$2.05, beat consensus on earnings and revenue, and paired this with a new US$400 million share repurchase authorization that has no expiration date. The business leaned on continued VYJUVEK demand, including a 30% year over year revenue lift and progress on European pricing, while early KB113 data in Gorlin syndrome added pipeline depth alongside some timing shifts for other programs. We will now look at...

      Nov 3Yahoo FinanceKRYS
      Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
      Nov 3Yahoo FinanceKRYS
      Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”
      Nov 3Yahoo FinanceKRYS
      Krystal Biotech Inc (KRYS) (Q3 2026) Earnings Call Highlights: Vyjuvek Revenue Jumps 30% to ...

      Krystal Biotech Inc (KRYS) posted strong double-digit Vyjuvek growth, authorized a $400 million share repurchase, and trimmed full-year expense guidance while advancing its pipeline.

      Nov 2Yahoo FinanceKRYS
      Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
      Nov 2MarketWatchKRYSVRTX
      Oracle, Intel among market cap stock movers on Monday
      Nov 2Investing.comINTCKRYSORCL
      Krystal Biotech Analyst Says Stock Weakness 'Overblown'
      Nov 2BenzingaKRYS
      Krystal Biotech, Inc. Q3 2026 Earnings Call Summary
      Nov 2Yahoo FinanceKRYS
      Krystal Biotech Q3 Earnings Call Highlights
      Nov 2Yahoo FinanceKRYS
      Krystal Biotech falls as data for pipeline programs pushed to 2027

      Krystal Biotech stock fell after delaying pipeline data to 2027 despite a Q3 earnings beat. Read more here.

      Nov 2Seeking AlphaKRYS
      Oracle, Alibaba among market cap stock movers on Monday
      Nov 2Investing.comKRYSBABAORCL
      Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

      Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 2Yahoo FinanceKRYS
      Earnings call transcript: Krystal Biotech tops Q3 2026 estimates, shares fall
      Nov 2Investing.comKRYS
      Krystal Biotech Q3 2026 Earnings Call Transcript
      Nov 2BenzingaKRYS
      Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth
      Nov 2Yahoo FinanceKRYS
      Krystal Biotech earnings beat by $0.21, revenue topped estimates
      Nov 2Investing.comKRYS
      Krystal Biotech stock falls nearly 4% despite third quarter earnings beat
      Nov 2Investing.comKRYS
      Krystal Biotech earnings up next: International expansion in focus
      Nov 2Investing.comKRYS
      Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
      Oct 30Yahoo FinanceKRYSOKTA
      BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
      Oct 28Yahoo FinanceBCRXKRYS
      Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
      Oct 26Yahoo FinanceKRYS
      INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB)
      Oct 23Seeking AlphaINMBKRYS
      Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
      Oct 22BenzingaKRYS
      BioCryst to Report Third Quarter 2026 Financial Results on November 4
      Oct 21Yahoo FinanceBCRXKRYS
      Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
      Oct 21Yahoo FinanceKRYS
      Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
      Oct 15BenzingaKRYS
      Krystal Biotech reports positive early data for Gorlin syndrome trial
      Oct 15Investing.comKRYS
      Krystal Biotech Says KB113 Demonstrates Significant Regression in Lesions in Gorlin Syndrome Pilot Study
      Oct 15Yahoo FinanceKRYS
      Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
      Oct 13MarketWatchKRYSVRTX
      Krystal Biotech Stock: VYJUVEK’s Success Is Becoming Its Growth Problem (Downgrade)

      Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.

      Oct 10Seeking AlphaKRYS
      Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value (NASDAQ:KRYS)

      Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here.

      Oct 10Seeking AlphaKRYS
      RBC Capital Sticks to Its Buy Rating for Krystal Biotech (KRYS)

      Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailKRYS
      What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
      Oct 8Yahoo FinanceKRYS
      Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
      Oct 8Yahoo FinanceKRYS
      Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run

      Krystal Biotech has produced a very large 5 year share price gain, which naturally puts the focus on whether that move is supported by the business it has built. With the stock now trading around US$324.57, the practical question for you is how well that market value lines up with the earnings the company is generating. A roughly 7x return over 5 years puts a lot of expectations into the price. The key issue is how firmly those expectations rest on current and future earnings power. The...

      Oct 8Yahoo FinanceKRYS
      $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today - Krystal Biotech (NASDAQ:KR

      Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market capitalization of

      Oct 6BenzingaKRYS
      Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?

      Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue. VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, or DEB, helps patients with an underlying genetic problem that leaves their skin extremely fragile and prone to chronic wounds. The […]

      Oct 6Yahoo FinanceKRYS
      Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Krystal Biotech (NAS

      Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization of

      Sep 25BenzingaKRYS
      Krystal Biotech stock initiated at buy by Goldman Sachs
      Sep 24Investing.comKRYS
      BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating

      Krystal Biotech (KRYS) has an average rating of buy and mean price target of $386, according to anal

      Sep 21Yahoo FinanceKRYS
      Krystal Biotech at Cantor healthcare conference: pipeline gains pace
      Sep 10Investing.comKRYS
      Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
      Sep 10BenzingaKRYS
      Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing

      Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on September 04, 2026,

      Sep 8Yahoo FinanceKRYS
      Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock
      Sep 5Investing.comKRYS
      Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock
      Sep 5Investing.comKRYS
      Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
      Sep 3Yahoo FinanceKRYS
      Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

      Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 2Yahoo FinanceKRYS

      This is the newest page. Registered accounts read further back.